Nepal | September 30, 2020

Sanofi, GSK launch trial for COVID-19 protein-based vaccine

Reuters
Share Now:
  • Phase 1/2 trial enrols 440 adults in the US
  • Final testing stage expected to start in December

PARIS: French drugmaker Sanofi and Britain’s GlaxoSmithKline said they had started a clinical trial of their protein-based COVID-19 vaccine candidate, and aimed to reach the final testing stage by December.

If the results are conclusive, Sanofi and GSK hope to get the vaccine approved in the first half of next year.

The trial is currently in a “Phase 1/2 study” aimed at evaluating the safety, tolerability and immune response of the vaccine in 440 healthy adults across 11 investigational sites in the United States.

The vaccine candidate uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the vaccine, made by GSK.

The two companies are scaling up manufacturing in order to be ready to produce up to one billion doses in 2021.

Drugmakers and government agencies worldwide are racing to develop vaccines and treatments for COVID-19, the illness caused by the new coronavirus, which has claimed more than 861,000 lives and crippled economic activity around the globe. (https://tmsnrt.rs/3aIRuz7)

Sanofi and GSK are not the first in the race – several vaccine candidates have already reached the final, wider testing stage known as “Phase 3” – but they believe their respective experience in the fields of vaccines is an advantage.

The French group is also working on another vaccine candidate to prevent COVID-19 with U.S. company Translate Bio which will rely on a different technology called mRNA.

In an interview with Reuters last week, Sanofi’s CEO Paul Hudson said readings of preclinical data had increased the group’s confidence in its two coronavirus vaccine candidates.

Sanofi and GSK have secured deals for the vaccine-plus-adjuvant with the United States and Britain, and are in advanced talks with the European Union to supply it with up to 300 million doses.

They also plan to supply COVAX, a COVID-19 vaccine and treatment allocation plan co-led by the World Health Organization (WHO) that aims to help buy and fairly distribute shots across the globe.

Earlier this month, Sanofi said a rheumatoid arthritis drug, Kevzara, had failed as a COVID-19 treatment.


Follow The Himalayan Times on Twitter and Facebook

Recommended Stories:

More from The Himalayan Times:

Two more Covid-19 related fatalities reported in Banke

RANJHA: Two more Covid-19 related deaths have been reported in Banke district on Tuesday. According to Naresh Shrestha, corona resource person at District Health Office, Banke, a 41-year-old man of Ranitalau in Nepalgunj Sub-Metropolitan City-7, and a 53-year-old man of Kohalpur Municipality-10 Read More...

Nepal's coronavirus cases top 75,000 on Tuesday with 1513 infections

KATHMANDU: Nepal’s coronavirus tally moved to 76,258 as 1,513 new infections were reported in the last 24 hours. Read Also: Kathmandu valley registers record-high 934 single-day coronavirus cases As many as 731 people that had earlier contracted Covid-19 tested negative for the infection as Read More...

Ten Covid-19 fatalities recorded, death-toll inches closer closer to 500

KATHMANDU: Ten people passed away from Covid-19 related complications in the last 24 hours, with which the nationwide death-toll has moved to 491. Three women and seven men lost their lives due to this infection, the Health Ministry’s latest update showed. Read Also: Kathmandu valley registe Read More...

Kathmandu valley registers record-high 934 single-day coronavirus cases

KATHMANDU: The number of single-day coronavirus infections detected in the three districts of Kathmandu valley exceeded 900 for the first time on Tuesday. As many as 934 cases surfaced in the valley in the last 24 hours, of which a majority 747 infections were registered in the capital alone. Read More...

Nepal to receive 25 mln Russian Covid-19 vaccine doses

KATHMANDU: Russia is set to supply 25 million doses of its potential Covid-19 vaccine to Nepal. The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund on Tuesday said that it will supply the Russian Sputnik V vaccine through Trinity Pharmaceuticals based in Nepal. The pres Read More...

Liverpool's Klopp bristles at Keane's "sloppy" criticism

LONDON: Liverpool manager Juergen Klopp hit back at television pundit and former Manchester United captain Roy Keane on Monday after the Irishman described the Premier League champions' defending in a 3-1 win over Arsenal on Monday as "sloppy". Liverpool have won all three of their league games s Read More...

Djokovic seeks French Open redemption after New York fiasco

PARIS: Three weeks after an acrimonious exit at the US Open, world number one Novak Djokovic will resume his pursuit of an 18th Grand Slam title when he takes on Sweden's Mikael Ymer in the first round at the French Open on Tuesday. The Serbian had started as a heavy favourite to win the title at Read More...

Youth held for raping minor in Rautahat

RAUTAHAT: A youth has been arrested on the charges of raping a 15-year-old girl in Rauthat, on Monday night. The victim's father filed a first incident report (FIR) against 35-year-old Indal Das at a nearby police station. Subsequently, the accused was apprehended from his house around mid-night Read More...